Abstract
Dual agonism of glucagon and glucagon-like peptide-1 (GLP-1) receptors reduces body weight without inducing hyperglycemia. In addition, coagonists have demonstrated lipid lowering property, which was independent of their anorectic effect. Similarly, GLP-1 modulates cardiovascular function which is favorable for treatment of myocardial injury, cardiac dysfunction, cardiac arrhythmias, endothelial dysfunction, and blood pressure, while glucagon has a positive impact on heart rate, cardiac output, ventricular contraction and enhances cardiac performance in animals and humans. Hence, researchers focused on combining these attributes of GLP-1 and glucagon in a single molecule, which was termed as a coagonist. Oxyntomodulin is the naturally occurring coagonist of GLP-1 and glucagon. This review focusses on the coagonists under clinical development discussing activities affecting cardiovascular functions, lipid modulation, direct effect on cardiac functions or other related functions. A comparative analysis of the in vitro and in vivo properties of GLP-1, glucagon and the coagonists is also carried out. This review discusses potential of GLP-1 and glucagon coagonists in treatment of cardiovascular and hemodynamic diseases with attention to GLP-1 or glucagon receptor specific properties as well as the interaction between other therapies.
Keywords: Cardiovascular effect, coagonist, GLP-1, Glucagon and oxyntomodulin.
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title:Therapeutic Potential of Coagonists of Glucagon and GLP-1
Volume: 12 Issue: 2
Author(s): Vishal J. Patel, Amit A. Joharapurkar, Samadhan G. Kshirsagar, Kartikkumar N. Patel, Gaurang B. Shah and Mukul R. Jain
Affiliation:
Keywords: Cardiovascular effect, coagonist, GLP-1, Glucagon and oxyntomodulin.
Abstract: Dual agonism of glucagon and glucagon-like peptide-1 (GLP-1) receptors reduces body weight without inducing hyperglycemia. In addition, coagonists have demonstrated lipid lowering property, which was independent of their anorectic effect. Similarly, GLP-1 modulates cardiovascular function which is favorable for treatment of myocardial injury, cardiac dysfunction, cardiac arrhythmias, endothelial dysfunction, and blood pressure, while glucagon has a positive impact on heart rate, cardiac output, ventricular contraction and enhances cardiac performance in animals and humans. Hence, researchers focused on combining these attributes of GLP-1 and glucagon in a single molecule, which was termed as a coagonist. Oxyntomodulin is the naturally occurring coagonist of GLP-1 and glucagon. This review focusses on the coagonists under clinical development discussing activities affecting cardiovascular functions, lipid modulation, direct effect on cardiac functions or other related functions. A comparative analysis of the in vitro and in vivo properties of GLP-1, glucagon and the coagonists is also carried out. This review discusses potential of GLP-1 and glucagon coagonists in treatment of cardiovascular and hemodynamic diseases with attention to GLP-1 or glucagon receptor specific properties as well as the interaction between other therapies.
Export Options
About this article
Cite this article as:
Patel J. Vishal, Joharapurkar A. Amit, Kshirsagar G. Samadhan, Patel N. Kartikkumar, Shah B. Gaurang and Jain R. Mukul, Therapeutic Potential of Coagonists of Glucagon and GLP-1, Cardiovascular & Hematological Agents in Medicinal Chemistry 2014; 12 (2) . https://dx.doi.org/10.2174/1871525712666141019194025
DOI https://dx.doi.org/10.2174/1871525712666141019194025 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
Call for Papers in Thematic Issues
Medicinal Plants with Beneficial Properties on Diabetes and Hypertension
Diabetes and hypertension are real scourges of the 21st century. It is imperative to act in order to find innovative solutions to this problem. Taking medications such as hypoglycemic and antihypertensive drugs may aggravate certain underlying comorbidities, such as chronic kidney disease and cardiovascular disease. This significant drawback therefore requires ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Frontotemporal Lobar Degeneration (FTLD): Review and Update for Clinical Neurologists
Current Alzheimer Research Treatment of the Cheyne-Stokes Breathing Pattern in Patients with Congestive Heart Failure: An Update
Current Respiratory Medicine Reviews It’s Time for An Epigenomics Roadmap of Heart Failure
Current Genomics Potential Role of microRNAs in Cardiovascular Disease: Are They up to Their Hype?
Current Cardiology Reviews Endoplasmic Reticulum Stress-induced Transcriptional Factor CHOP and Cardiovascular Diseases
Current Hypertension Reviews MicroRNAs as Diagnostic, Prognostic and Predictive Biomarkers of Cardiac Disease
Recent Patents on Biomarkers Alteration of the Beta-Adrenergic Signaling Pathway in Human Heart Failure
Current Pharmaceutical Biotechnology Interest of Antioxidant Agents in Parasitic Diseases. The Case Study of Coumarins
Current Topics in Medicinal Chemistry Synthesis and Pharmacological Profile of an Orally-Active Growth Hormone Secretagogue, SM-130686
Combinatorial Chemistry & High Throughput Screening Inflammatory Mediators and the Failing Heart: A Translational Approach
Current Molecular Medicine Proinflammatory Gene Polymorphisms and Ischemic Stroke
Current Pharmaceutical Design Physicians’ Perception About Use of Vitamin B12 in the Treatment or Prevention of Diabetic Neuropathy: A Cross-sectional Survey in Saudi Arabia
Current Diabetes Reviews MicroRNAs and Cardiac Conduction
Current Drug Targets Endogenous Repair System of Oxidative Damage of DNA
Current Chemical Biology The Resurgence of Aldosterone in Hypertension and Cardiovascular Disease
Current Hypertension Reviews Antiangiogenic Therapy in Malignant Glioma: Promise and Challenge
Current Pharmaceutical Design Mitochondrial Involvement in Psychiatric Illness in Adults
Current Psychiatry Reviews Atrial Fibrillation with a Focus on Oral Antiarrhythmic Therapy
Current Drug Therapy Structure Based Drug Design of Angiotensin-I Converting Enzyme Inhibitors
Current Medicinal Chemistry Lipid Lowering Agents and the Endothelium: An Update after 4 Years
Current Vascular Pharmacology